Search the Newsreel

Ironwood Pharmaceuticals, Inc. $IRWD Shares Sold by Amundi

Ironwood Pharmaceuticals (IRWD) Stock Faces A Sentiment Check After Raised Guidance

State Street Corporation (NYSE: IRWD caretaker) holds 5.4% of Ironwood common stock

State Street Corporation has disclosed a 5.4% stake in Ironwood Pharmaceuticals common stock through a passive Schedule 13G filing. The investment manager beneficially owns 8,809,601 shares, primarily with shared voting and dispositive power through its subsidiaries. This significant ownership makes State Street a key …

Ironwood Pharmaceuticals (IRWD) Is Up 14.2% After Raising 2026 Revenue Guidance – Has The Bull Case Changed?

Ironwood Pharmaceuticals, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:IRWD) 2026-08-06

Is Ironwood Pharmaceuticals (IRWD) Undervalued After Q2 Earnings

Ironwood Pharmaceuticals (IRWD) Q2 Earnings Top Estimates

Ironwood Pharmaceuticals Raises 2026 Full-Year Financial Guidance Building on Strong Second Quarter Results

Ironwood Pharmaceuticals reported strong second-quarter 2026 results, leading the company to raise its full-year financial guidance for LINZESS U.S. net sales, total revenue, and adjusted EBITDA. The company also announced the initiation of the confirmatory Phase 3 STARS-2 trial for apraglutide in short bowel …

Ironwood Pharmaceuticals (NASDAQ:IRWD) Sees Large Volume Increase - What's Next?

Ironwood Pharmaceuticals (NASDAQ:IRWD) Stock Price Up 8.7% - Should You Buy?

BlackRock, Inc. (NASDAQ: IRWD) discloses 8.1% beneficial stake in Ironwood

BlackRock, Inc. has filed an amended Schedule 13G, disclosing an 8.1% beneficial ownership stake in Ironwood Pharmaceuticals Inc, totaling 13,373,568 shares of Class A stock. BlackRock exercises sole voting power over 13,195,313 shares and sole dispositive power over all 13,373,568 shares. The filing specifies …

Return on assets % of Ironwood Pharmaceuticals, Inc. Class A – HAM:I76

The article provides financial data specifically focusing on the Return on Assets (%) for Ironwood Pharmaceuticals, Inc. Class A, traded under the symbol I76 on the Hamburg Stock Exchange. It indicates historical values and changes for this metric, noting that the market is currently …

Total operating expenses of Ironwood Pharmaceuticals, Inc. Class A – HAM:I76

This article states the total operating expenses for Ironwood Pharmaceuticals, Inc. Class A, traded on the Hamburg Stock Exchange under the ticker I76. It indicates that the market is closed with no current trades. Further financial details would be available in a dedicated "Financials" …

Ironwood Pharmaceuticals, Inc. Class A Revenue Breakdown – BX:I76

Ironwood Pharmaceuticals, Inc. Class A (I76 BX Swiss) generated 234.78 million CHF last year, primarily from its Human Therapeutics segment. This represents a decrease from the previous year's 319.15 million CHF. The United States was the largest contributor to revenue, accounting for 229.38 million …

Ironwood Pharmaceuticals, Inc. Class A Revenue Breakdown – SWB:I76

Ironwood Pharmaceuticals, Inc. (SWB:I76) generated €252.15 million in revenue last year, primarily from its Human Therapeutics segment. This marks a decrease from the previous year's €339.45 million, with the United States contributing the majority of the revenue.

Ironwood Pharmaceuticals (IRWD) grants 137,036-share RSU new-hire award to CMO

Ironwood Pharmaceuticals Inc. (IRWD) has granted its SVP, CMO, and Head of Research & Drug Development, Jeffrey Silber, a new-hire restricted stock unit (RSU) award covering 137,036 shares of Class A Common Stock. This award vests 25% annually over four years and was issued …